Loperamide 1980s, prior to the expiration of US patent on 30 January 1990, McNeil company started to develop Imodium Advanced containing loperamide and simethicone for treating both diarrhea and gas. In March 1997, the company patented such combination. The drug was approved in June 1997 by the FDA as Imodium Multi-Symptom Relief in the form of a chewable tablet. In November 1993, loperamide was launched as an orally disintegrating tablet based on Zydis technology. Imodium Instant Melts from Johnson & Johnson is currently the only loperamide available in the form of orally disintegrating tablets. In 2013, loperamide in the form of
Facility condition index was a strictly informal tool that Thomas and Richardson used while working for the Navy. It was developed and adopted as an industry benchmark by AME. To calculate an FCI a facility manager needs to quantify the cost of maintenance, repair and replacement deficiencies. This is typically the outcome of a Facility Condition Assessment. The current replacement value is defined as what monetary value the organization places on the facility. The FCI is a relative indicator of condition, and should be tracked over time to maximize its benefit. It is advantageous to define condition ratings based on ranges of the